Innovaderm versterkt Europese aanwezigheid met twee nieuw opgerichte operationele hubs (Spanje en Polen)
Sterke organische groei leidt ertoe dat dermatologie CRO de klinische proeven in de EU aanzienlijk vergroot
MONTREAL–(BUSINESS WIRE)– Innovaderm heeft vandaag aangekondigd dat haar strategische Europese expansie-initiatief een belangrijke mijlpaal heeft bereikt met de lancering van twee belangrijke operationele centra in Polen en Spanje.
Biotechnologische en farmaceutische bedrijven kunnen officieel samenwerken met het CRO-team van experts in Europa om klinische onderzoeken naar psoriasis, acne, atopische dermatitis en andere dermatologische indicaties te beheren. Dit omvat naleving van strikte wettelijke vereisten, werving van patiënten, selectie van locaties, klinische monitoring en het schrijven van protocollen.
“Tot op heden hebben we met succes meer dan 500 klinische onderzoeken afgerond op 2.900 locaties met meer dan 85.000 patiënten”, zegt Dave Selkirk, Chief Operating Officer van Innovaderm. “De aanwezigheid van twee operationele hubs in Europa zal ons in staat stellen een stap verder te gaan en de ontwikkeling van veelbelovende therapieën die het potentieel hebben om levens te veranderen, te versnellen. Als we naar de toekomst kijken, is ons doel om innovatie in onderzoek en het toenemende aantal patiënten met huidaandoeningen wereldwijd te blijven ondersteunen.”
Innovaderm Bolsters European Presence With Two Newly-Established Operations Hubs (Spain & Poland)
Strong organic growth leads dermatology CRO to significantly augment clinical trials in EU
MONTREAL–(BUSINESS WIRE)– Innovaderm announced today that its strategic European expansion initiative has reached a major milestone with the launch of two key centres of operations in Poland and Spain.
Biotechnology and pharmaceutical companies can officially partner with the CRO’s team of experts in Europe to manage clinical trials in psoriasis, acne, atopic dermatitis and other dermatology indications. This includes adherence to stringent regulatory requirements, patient recruitment, site selection, clinical monitoring and protocol writing.
“To date, we have successfully completed more than 500 clinical trials at 2,900 sites involving more than 85,000 patients,” says Dave Selkirk, Innovaderm’s Chief Operating Officer. “The presence of two operations hubs in Europe will allow us to go one step further and accelerate the development of promising therapies that have the potential to transform lives. As we look to the future, our goal is to continue supporting innovation in research and the increasing number of patients with skin conditions worldwide.”
“These are exciting times for Innovaderm,” adds Anne Marie Gaulin, Chief Business Officer. “Our highly skilled employees are specialized in dermatology and understand the nuances of deep regional and pan-European requirements. With its site network, medical expertise, and established KOL relationships, Innovaderm’s team in Europe is ready to help customers advance the next generation of dermatology treatments.”
Innovaderm is one of the largest, independent, full-service CROs in the field of dermatology with early to late phase clinical trial capabilities in 30+ indications. For more information, visit our website.
Innovaderm Research Inc.
Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.
Contacts
Kathy Giangaspero
Communications Specialist
Innovaderm Research Inc.